Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | FBP1 | P09467 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 7/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30074835 | 0.86 | PTGES (0.44) | MAPTMAPK1PTGESGAAALDH1A1 | |
| SCHEMBL20475933 | 0.86 | PTGES (0.44) | MAPTMAPK1PTGESGAAALDH1A1 | |
| SCHEMBL22558817 | 0.86 | MAPT (0.44) | MAPTMAPK1TDP1L3MBTL1NPSR1 | |
| SCHEMBL26619715 | 0.84 | PTGES (0.44) | PTGESFBP1HTTEGFRLMNA | |
| SCHEMBL1490236 | 0.83 | MAPT (0.46) | MAPTMAPK1TDP1L3MBTL1PTGES | |
| SCHEMBL4726732 | 0.83 | MAPT (0.45) | MAPTMAPK1TDP1L3MBTL1GAA | |
| SCHEMBL15215126 | 0.82 | PTGES (0.46) | MAPTPTGESFBP1CYP1A2CYP2C19 | |
| SCHEMBL2368975 | 0.82 | ALDH1A1 (0.39) | MAPTMAPK1TDP1L3MBTL1PTGES | |
| SCHEMBL3862496 | 0.81 | PTGES (0.41) | MAPTMAPK1PTGESALDH1A1FBP1 | |
| SCHEMBL6760464 | 0.81 | PTGES (0.43) | MAPTPTGESALDH1A1FBP1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598192-B2 | Hydroxylamine substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-12-03 | — | — | US | disclosed |
| US-7897767-B2 | Oxime substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| US-7598382-B2 | Aryl substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| EP-1682544-A4 | HYDROXYLAMINE SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M INNOVATIVE PROPERTIES CO (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20090105295-A1 | HYDROXYLAMINE SUBSTITUTED IMIDAZOQUINOLINES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090042925-A1 | OXIME SUBSTITUTED IMIDAZOQUINOLINES | COLEY PHARMACEUTICAL GROUP, INC. | 2009-02-12 | — | — | US | disclosed |
| EP-1685129-A4 | OXIME SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M INNOVATIVE PROPERTIES CO (US) | 2008-10-22 | — | — | EP | disclosed |
| CN-1906192-A | Hydroxylamine substituted imidazo ring compounds | 3M INNOVATIVE PROPERTIES CO (US) | 2007-01-31 | — | — | CN | disclosed |
| CN-1906193-A | Oxime substituted imidazo ring compounds | 3M INNOVATIVE PROPERTIES CO (US) | 2007-01-31 | — | — | CN | disclosed |
| US-7091214-B2 | Aryl substituted Imidazoquinolines | 3M INNOVATIVE PROPERTIES CO. (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1685129-A2 | OXIME SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M Innovative Properties Company (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1682544-A2 | HYDROXYLAMINE SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M Innovative Properties Company (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20060111387-A1 | ARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY | 2006-05-25 | — | — | US | disclosed |
| EP-1590348-A1 | ARYL / HETARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2005-11-02 | — | — | EP | disclosed |
| WO-2005048933-A2 | OXIME SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005048945-A2 | HYDROXYLAMINE SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
| US-20040147543-A1 | Aryl substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-07-29 | — | — | US | disclosed |
| WO-2004058759-A1 | ARYL / HETARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105295-A1 | HYDROXYLAMINE SUBSTITUTED IMIDAZOQUINOLINES | IL2, IL4, IFNG | MAPT 4183/4885MAPK1 1872/4885TDP1 2911/4885 |
| US-20090042925-A1 | OXIME SUBSTITUTED IMIDAZOQUINOLINES | IFNG, IL2, IRF3 | MAPT 4247/4885MAPK1 1865/4885TDP1 3168/4885 |
| US-20040147543-A1 | Aryl substituted imidazoquinolines | IL2, IFNG, IRF3 | MAPT 4429/4885MAPK1 2202/4885TDP1 3524/4885 |
| US-20060111387-A1 | ARYL SUBSTITUTED IMIDAZOQUINOLINES | IL2, IFNG, IRF3 | MAPT 4429/4885MAPK1 2202/4885TDP1 3524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.